Alvogen Korea to have dominant say at Kunwha

Published: 2012-12-17 06:56:00

Updated: 2012-12-17 06:56:00

Alvogen Korea, a Korean unit of U.S.-based generic firm Alvogen, will have a dominant say in business decisions at Kunwha Pharma having with 60 billion won in sales, from now on.

A decision by shareholders of Kunwha Thursday sees Alvogen Korea represented by five seats on the Korean company’s ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK